Spyre Therapeutics, Inc. $(SYRE)$, a clinical-stage biotechnology company, has announced positive interim results from its Phase 1 trials for two novel extended half-life monoclonal antibodies, SPY002 and SPY072, targeting TL1A. These results were presented on June 17, 2025, during a conference call and webcast. The antibodies demonstrated good tolerability, a half-life of approximately 75 days, and effective target engagement for up to 20 weeks. In addition, Spyre has initiated the SKYLINE-UC platform trial, evaluating treatments for ulcerative colitis, and plans to start the SKYWAY-RD basket trial in Q3 2025, which will assess SPY072 in several rheumatologic conditions. Topline proof-of-concept data are expected in 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.